Compare LEN & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | ALNY |
|---|---|---|
| Founded | 1954 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 21.6B |
| IPO Year | 1996 | 2004 |
| Metric | LEN | ALNY |
|---|---|---|
| Price | $83.80 | $159.75 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 21 | 30 |
| Target Price | $77.27 | ★ $299.96 |
| AVG Volume (30 Days) | ★ 3.6M | 3.1M |
| Earning Date | 12-15-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | 3.36 | ★ 18.42 |
| Revenue | ★ $34,186,934,000.00 | $1,037,418,000.00 |
| Revenue This Year | N/A | $46.57 |
| Revenue Next Year | $1.12 | $19.91 |
| P/E Ratio | $24.87 | ★ $8.93 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $71.78 | $149.18 |
| 52 Week High | $133.76 | $479.79 |
| Indicator | LEN | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 31.82 |
| Support Level | $82.96 | N/A |
| Resistance Level | $84.25 | $237.47 |
| Average True Range (ATR) | 3.12 | 10.64 |
| MACD | -0.65 | -0.10 |
| Stochastic Oscillator | 11.11 | 12.91 |
Lennar is the second-largest public homebuilder in the United States, behind D.R. Horton, operating in 26 states. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.